Literature DB >> 17990938

Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study.

Floyd H Gilles1, C Jane Tavaré, Laurence E Becker, Peter C Burger, Allan J Yates, Ian F Pollack, Jonathan L Finlay.   

Abstract

In the Children's Cancer Group-945 trial, study design allowed estimation of overall interpathologist observational agreement for 6 histologic features frequently used in brain tumor diagnoses. We evaluated agreement between pairs of 5 experienced neuropathologists, who had knowledge of the general diagnoses prior to slide readings. We performed this study in an attempt to further improve pathologist interinstitutional agreement. The features mitosis, necrosis, and giant cells had "fair" overall kappa estimates of reproducibility of around 0.5, while endothelial proliferation had only a "poor" overall kappa of 0.35. The Rogot reproducibility index averaged 0.5 for pleomorphism and hyperchromia. The upper bounds for the 10 pair summary agreement estimates were at best 0.65 ("good") for all 6 features. These relatively low-reproducibility estimates for the very small number of histologic features being assessed in tumors institutionally diagnosed as high-grade gliomas indicate that neuropathologists either used different operational definitions or interpreted them differently. We found that we could rank the histologic features from best to worst agreement among study pathologists as necrosis, giant cells, mitosis, endothelial proliferation, hyperchromic nuclei, and pleomorphic cells. We suggest that neuropathologists involved in multi-institutional studies of putative therapies not discard these traditional histologic features, but rather develop standardized operational definitions and measure their variability before beginning the studies. Only after such histologic feature variability studies are conducted will we have the data to identify specific histologic features of value to clinicians and researchers. Agreement and strict adherence to improved nonsubjective diagnostic criteria would improve histologic feature reliability and, consequently, their usefulness in studies.

Entities:  

Mesh:

Year:  2007        PMID: 17990938     DOI: 10.2350/07-06-0303.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  22 in total

1.  Computer vision approach to morphometric feature analysis of basal cell nuclei for evaluating malignant potentiality of oral submucous fibrosis.

Authors:  M Muthu Rama Krishnan; Mousumi Pal; Ranjan Rashmi Paul; Chandan Chakraborty; Jyotirmoy Chatterjee; Ajoy K Ray
Journal:  J Med Syst       Date:  2010-12-09       Impact factor: 4.460

Review 2.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

3.  The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience.

Authors:  Eric Bouffet; Jeffrey C Allen; James M Boyett; Allen Yates; Floyd Gilles; Peter C Burger; Richard L Davis; Laurence E Becker; Ian F Pollack; Jonathan L Finlay
Journal:  J Neurosurg Pediatr       Date:  2015-12-18       Impact factor: 2.375

Review 4.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

5.  What is better/reliable, mitosis counting or Ki67/MIB1 staining?

Authors:  Mark Kriegsmann; Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2016-10

6.  Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Yujin Hoshida; Shakti Ramkissoon; Lori Ramkissoon; Benjamin Rich; Cecile L Maire; Brenton R Paolella; Steven E Schumacher; Barbara Tabak; Ruben Ferrer-Luna; Memet Ozek; Aydin Sav; Sandro Santagata; Patrick Yung Wen; Liliana C Goumnerova; Azra H Ligon; Charles Stiles; Rosalind Segal; Todd Golub; Jacques Grill; Keith L Ligon; Jennifer A Chan; Mark W Kieran; Rameen Beroukhim
Journal:  Neuro Oncol       Date:  2015-03-29       Impact factor: 12.300

7.  Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.

Authors:  David D Eisenstat; Ian F Pollack; Alain Demers; Mark V Sapp; Pascal Lambert; James D Weisfeld-Adams; Peter C Burger; Floyd Gilles; Richard L Davis; Roger Packer; James M Boyett; Jonathan L Finlay
Journal:  J Neurooncol       Date:  2014-11-28       Impact factor: 4.130

8.  The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium.

Authors:  E Susan Amirian; Georgina N Armstrong; Renke Zhou; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Michael E Scheurer; Kenneth Aldape; Irina Alafuzoff; Thomas Brännström; Helle Broholm; Peter Collins; Caterina Giannini; Marc Rosenblum; Tarik Tihan; Beatrice S Melin; Melissa L Bondy
Journal:  Am J Epidemiol       Date:  2015-12-10       Impact factor: 4.897

9.  Pediatric thalamic tumors in the MRI era: a Canadian perspective.

Authors:  Paul Steinbok; Chittur Viswanathan Gopalakrishnan; Alexander R Hengel; Aleksander M Vitali; Ken Poskitt; Cynthia Hawkins; James Drake; Maria Lamberti-Pasculli; Olufemi Ajani; Walter Hader; Vivek Mehta; P Daniel McNeely; Patrick J McDonald; Adrianna Ranger; Michael Vassilyadi; Jeff Atkinson; Scott Ryall; David D Eisenstat; Juliette Hukin
Journal:  Childs Nerv Syst       Date:  2015-11-23       Impact factor: 1.475

10.  Pineal gland tumors: experience from the SEER database.

Authors:  Maysa Al-Hussaini; Iyad Sultan; Najyah Abuirmileh; Imad Jaradat; Ibrahim Qaddoumi
Journal:  J Neurooncol       Date:  2009-04-17       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.